Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

MDGL

Madrigal Pharmaceuticals Inc

Nov 27 • 04:00PM ET

331.45

Dollar change -5.29
Percentage change -1.57	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD AKRO VKTX NBIX ENTA SLDB LXRX TSHA IMAB RDHL

| Held by: XBI IWM VTI VB VBR VXF IWO IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-25.07	Insider Own	15.75%	Shs Outstand	19.88M	Perf Week	4.53%
Market Cap	7.12B	Forward P/E	-	EPS next Y	-13.65	Insider Trans	-0.70%	Shs Float	18.38M	Perf Month	52.19%
Income	-518.67M	PEG	-	EPS next Q	-4.56	Inst Own	104.28%	Short Float	24.13%	Perf Quarter	33.26%
Sales	76.81M	P/S	92.64	EPS this Y	-21.06%	Inst Trans	0.43%	Short Ratio	11.33	Perf Half Y	46.99%
Book/sh	35.64	P/B	9.30	EPS next Y	43.60%	ROA	-79.11%	Short Interest	4.43M	Perf Year	73.59%
Cash/sh	46.75	P/C	7.09	EPS next 5Y	0.00%	ROE	-129.76%	52W Range	168.25 - 368.29	Perf YTD	43.25%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-55.24%	ROI	-57.92%	52W High	-10.00%	Beta	-0.42
Dividend TTM	-	Quick Ratio	5.93	Sales past 5Y	0.00%	Gross Margin	95.23%	52W Low	97.00%	ATR (14)	17.02
Dividend Ex-Date	-	Current Ratio	5.98	EPS Y/Y TTM	-30.31%	Oper. Margin	-713.49%	RSI (14)	61.71	Volatility	4.96% 6.91%
Employees	376	Debt/Eq	0.15	Sales Y/Y TTM	-	Profit Margin	-675.24%	Recom	1.53	Target Price	372.20
Option/Short	Yes / Yes	LT Debt/Eq	0.15	EPS Q/Q	7.96%	Payout	-	Rel Volume	0.69	Prev Close	336.74
Sales Surprise	79.76%	EPS Surprise	27.09%	Sales Q/Q	-	Earnings	Oct 31 BMO	Avg Volume	391.49K	Price	331.45
SMA20	1.96%	SMA50	28.14%	SMA200	31.91%	Trades		Volume	269,299	Change	-1.57%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-28-24	Initiated	Cantor Fitzgerald	Neutral
Jun-11-24	Initiated	Wolfe Research	Outperform	$382
Apr-22-24	Initiated	BofA Securities	Underperform	$150
Mar-15-24	Upgrade	B. Riley Securities	Sell → Neutral	$155 → $270
Mar-06-24	Initiated	Citigroup	Buy	$382
Feb-26-24	Downgrade	B. Riley Securities	Neutral → Sell	$155
Dec-20-22	Reiterated	Oppenheimer	Outperform	$170 → $250
Dec-19-22	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-22	Reiterated	Piper Sandler	Overweight	$203 → $280
Dec-19-22	Reiterated	H.C. Wainwright	Buy	$170 → $225
Jul-08-22	Downgrade	B. Riley Securities	Buy → Neutral	$131 → $75
Oct-07-21	Initiated	Jefferies	Buy	$151
Aug-06-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
May-20-21	Resumed	Goldman	Buy	$195
Nov-24-20	Resumed	Evercore ISI	Outperform	$180
Nov-06-20	Reiterated	H.C. Wainwright	Buy	$165 → $184
Jul-31-20	Initiated	Piper Sandler	Overweight	$208
Jun-05-20	Initiated	BMO Capital Markets	Market Perform	$135
May-05-20	Initiated	Chardan Capital Markets	Buy	$205
Jan-30-20	Initiated	Canaccord Genuity	Buy	$198

Show Previous Ratings

Nov-23-24 07:46AM	3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move (Motley Fool)
Nov-22-24 09:55AM	Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy? (Zacks) +5.53%
Nov-21-24 05:12PM	Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024? (Insider Monkey)
Nov-18-24 02:53AM	The first MASH drug could open the door for others including GLP-1s (Pharma Voice) +5.17%
Nov-14-24 09:12PM	John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC (GuruFocus.com)
09:30AM	Loading…
Nov-10-24 09:30AM	1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More (Motley Fool)
Nov-06-24 08:00AM	Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 09:55AM	Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations (GuruFocus.com)
Nov-02-24 12:00PM	Madrigal, 89Bio jump after Novos semaglutide shows promise in MASH (TipRanks)
Nov-01-24 04:17PM	Madrigal Pharmaceuticals stock jumps on MASH drug hopes (Yahoo Finance Video) +23.23%
04:08PM	Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH (Investor's Business Daily)
03:03AM	Madrigal Pharmaceuticals Inc (MDGL) Q3 2024 Earnings Call Highlights: Strong Sales and ... (GuruFocus.com)
Oct-31-24 07:28AM	Madrigal: Q3 Earnings Snapshot (Associated Press Finance) +20.10%
07:00AM	Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Oct-30-24 08:00AM	Madrigal Pharmaceuticals to Present Multiple Rezdiffra (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting (GlobeNewswire)
06:53AM	Loading…
Oct-22-24 06:53AM	Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug (Clinical Trials Arena)
Oct-21-24 08:00AM	Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis (GlobeNewswire)
Oct-18-24 08:00AM	Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 (GlobeNewswire)
Oct-16-24 08:44AM	Madrigal Pharmaceuticals (MDGL): Leading the NASH Treatment Revolution with Rezdiffra (Insider Monkey)
Oct-02-24 08:00AM	Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference (GlobeNewswire)
Oct-01-24 08:00AM	Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development (GlobeNewswire)
Sep-30-24 08:00AM	Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra (resmetirom) (GlobeNewswire)
Sep-25-24 12:03AM	Is Madrigal Pharmaceuticals, Inc. (MDGL) the Best Guru Stock To Buy Now? (Insider Monkey)
Aug-26-24 08:00AM	Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-17-24 10:15AM	Is Madrigal Pharmaceuticals Stock a Buy? (Motley Fool)
Aug-14-24 11:55PM	John Paulson's Strategic Exits and Key Investments in Q2 2024: Spotlight on Newmark Group Inc (GuruFocus.com)
06:00AM	This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock (Motley Fool)
Aug-13-24 11:33AM	Madrigal plans to solidify Rezdiffras position in MASH despite start being slower than expected (Pharmaceutical Technology)
Aug-08-24 03:47AM	Q2 2024 Madrigal Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-24 04:14PM	Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains' (Investor's Business Daily) -12.18%
11:12AM	Loading…
11:12AM	Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line (Zacks)
07:20AM	Madrigal: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
06:30AM	Madrigals MASH drug launch gets off to a fast start (BioPharma Dive)
Aug-05-24 06:30AM	Is It Too Late to Buy Madrigal Pharmaceuticals Stock? (Motley Fool) -5.78%
Aug-02-24 07:00AM	Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel (GlobeNewswire)
Jul-24-24 08:00AM	Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024 (GlobeNewswire)
Jul-23-24 02:57PM	7 Biotech Stocks to Keep on Your Clinical Radar (InvestorPlace)
Jun-30-24 12:02PM	Is Madrigal Pharmaceuticals a Millionaire Maker? (Motley Fool)
Jun-28-24 06:45AM	Is Madrigal Pharmaceuticals Stock a Buy? (Motley Fool)
Jun-16-24 12:05PM	Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word. (Motley Fool)
Jun-15-24 09:45AM	Where Will Madrigal Pharmaceuticals Be in 3 Years? (Motley Fool)
Jun-12-24 03:56PM	Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily)
Jun-10-24 09:45AM	Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals (Motley Fool)
Jun-06-24 08:00AM	Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra (resmetirom) Presented at the EASL Congress (GlobeNewswire)
Jun-05-24 04:10PM	Madrigal, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH (Investor's Business Daily)
03:17PM	What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? (Benzinga)
10:56AM	Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH (Investor's Business Daily)
08:00AM	Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-29-24 08:00AM	Madrigal Pharmaceuticals to Present Multiple Rezdiffra (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress (GlobeNewswire)
May-24-24 03:17AM	Insider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, Chief Pharmaceutical ... (GuruFocus.com)
May-21-24 09:45AM	Is Madrigal Pharmaceuticals Stock a Buy? (Motley Fool)
May-17-24 03:08AM	Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing (MT Newswires)
May-15-24 09:19PM	John Paulson's Strategic Moves in Q1 2024 Highlight Madrigal Pharmaceuticals' Prominent Role (GuruFocus.com)
May-10-24 08:51AM	B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating (MT Newswires)
May-09-24 10:53AM	UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating (MT Newswires)
May-08-24 01:23PM	Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:02AM	Madrigal Pharmaceuticals Inc (MDGL) (Q1 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-07-24 09:18AM	Sector Update: Health Care Stocks Steady Pre-Bell Tuesday (MT Newswires) -7.48%
08:34AM	Madrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Rezdiffra Launch (GuruFocus.com)
08:08AM	Madrigal Pharmaceuticals Q1 Loss Widens; Shares Fall Pre-Bell (MT Newswires)
07:17AM	Madrigal: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Apr-24-24 04:00PM	Madrigal Statement on the Passing of Dr. Stephen Harrison (GlobeNewswire) -6.29% -5.02%
Apr-23-24 08:00AM	Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 (GlobeNewswire)
Apr-22-24 06:00AM	6 Stocks Positioned to Soar as Investors Focus on MASH (News Direct)
Apr-16-24 04:05PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-15-24 04:28PM	Latest Insider Selling in April 2024: 10 Stocks to Watch (Insider Monkey)
Apr-09-24 08:00AM	Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis (GlobeNewswire)
Apr-05-24 07:15AM	Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics (Motley Fool)
Apr-04-24 01:55AM	Madrigal Pharmaceuticals Inc Director James Daly Sells 32,489 Shares (GuruFocus.com)
01:54AM	Madrigal Pharmaceuticals Inc Director Richard Levy Sells 11,000 Shares (GuruFocus.com)
01:54AM	Madrigal Pharmaceuticals Inc Director Kenneth Bate Sells 32,489 Shares (GuruFocus.com)
Apr-03-24 04:05PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:45AM	1 No-Brainer Growth Stock to Buy Now (Motley Fool)
Apr-01-24 09:09PM	The 3 Best Biotech Stocks to Buy in April 2024 (InvestorPlace)
09:59AM	ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 09:00AM	Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals (Motley Fool)
04:43AM	Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval? (Motley Fool)
Mar-26-24 09:53AM	Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock (Motley Fool)
Mar-22-24 06:15AM	This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy? (Motley Fool)
Mar-19-24 05:50AM	Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win? (Motley Fool) -6.20%
Mar-18-24 11:58PM	Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering (GlobeNewswire)
08:01PM	7 Biotech Stocks Ready to Ride the Sectors Resurgence (InvestorPlace)
04:47PM	UPDATE 1-Madrigal plans $500 million fund raising to prepare for NASH drug launch (Reuters)
04:12PM	Madrigal commences $500 million public offering of common stock (Reuters)
04:04PM	Madrigal Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
03:15PM	Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark (Investor's Business Daily)
07:00AM	Ozempic Cant Do It AllA Potential New Blockbuster Is a Reminder of That (The Wall Street Journal)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
05:50AM	Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? (Motley Fool)
Mar-15-24 04:35PM	Wegovy and Zepbound Cast Shadow Over Madrigals Liver Drug (Barrons.com) +11.00%
04:14PM	Madrigal Stock Soars 11% After FDA Approved The First MASH Treatment (Investor's Business Daily)
03:50PM	Geron, Madrigal Pharmaceuticals jump on good news from FDA (Yahoo Finance Video)
02:34PM	Madrigal Pharmaceuticals Stock Surges After FDA Approves Liver Disease Treatment (The Wall Street Journal)
01:45PM	Madrigal Pharmaceuticals Soars After Getting FDA Approval for Liver-Scarring Treatment (Investopedia)
12:56PM	Top Stock Movers Now: Adobe, Ulta Beauty, Jabil, and More (Investopedia)
12:09PM	US STOCKS-Wall St slides as inflation woes dampen rate-cut bets (Reuters)
10:17AM	MDGL Stock Alert: The Historic Reason Madrigal Is Up 19% Today (InvestorPlace)
10:01AM	Madrigal Can Market the First Drug for Obesity-Scarred Livers. The Stock Soars. (Barrons.com)

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on March 2000 and is headquartered in West Conshohocken, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CRAVES FRED B	Director	Nov 25 '24	Sale	350.30	3,400	1,191,028	14,600	Nov 27 04:16 PM
CRAVES FRED B	Director	Nov 25 '24	Proposed Sale	322.73	10,000	3,227,300		Nov 25 04:10 PM
Huntsman Carole	Chief Commercial Officer	Nov 21 '24	Sale	316.92	688	218,041	10,785	Nov 22 04:30 PM
Carole Huntsman	Officer	Nov 21 '24	Proposed Sale	316.92	688	218,040		Nov 21 04:30 PM
Levy Richard S	Director	Nov 07 '24	Option Exercise	7.36	5,000	36,800	16,012	Nov 08 05:07 PM
Levy Richard S	Director	Nov 07 '24	Sale	350.00	5,000	1,750,000	11,012	Nov 08 05:07 PM
RICHARD S LEVY	Director	Nov 07 '24	Proposed Sale	338.22	5,000	1,691,100		Nov 07 04:36 PM
Levy Richard S	Director	Nov 01 '24	Option Exercise	7.36	5,000	36,800	16,012	Nov 05 07:01 PM
Levy Richard S	Director	Nov 01 '24	Sale	300.94	5,000	1,504,703	11,012	Nov 05 07:01 PM
RICHARD S LEVY	Director	Nov 01 '24	Proposed Sale	259.34	5,000	1,296,700		Nov 01 04:47 PM
Sibold William John	President and CEO	Sep 09 '24	Sale	243.83	6,363	1,551,490	55,887	Sep 11 09:51 PM
William John Sibold	Officer	Sep 09 '24	Proposed Sale	243.83	6,363	1,551,514		Sep 10 09:29 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 14 '24	Option Exercise	87.09	1,900	165,471	7,400	Jun 18 09:39 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 14 '24	Sale	280.00	1,900	532,000	5,500	Jun 18 09:39 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 12 '24	Option Exercise	87.92	2,000	175,840	7,500	Jun 14 09:44 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 12 '24	Sale	285.00	2,000	570,000	5,500	Jun 14 09:44 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	May 21 '24	Sale	231.34	1,036	239,668	5,500	May 23 09:36 PM
CRAVES FRED B	Director	May 14 '24	Option Exercise	103.02	22,489	2,316,844	435,851	May 16 09:53 PM
CRAVES FRED B	Director	May 14 '24	Sale	212.88	22,489	4,787,404	413,362	May 16 09:53 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 08 '24	Option Exercise	9.45	2,676	25,288	461,675	Apr 10 08:53 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 08 '24	Sale	245.99	2,676	658,258	458,999	Apr 10 08:53 PM
FRIEDMAN PAUL A	Director	Apr 08 '24	Option Exercise	9.45	26,270	248,251	212,005	Apr 10 08:50 PM
FRIEDMAN PAUL A	Director	Apr 08 '24	Sale	246.19	26,270	6,467,491	185,735	Apr 10 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 03 '24	Option Exercise	9.45	27,845	263,135	486,844	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 05 '24	Option Exercise	9.45	27,506	259,932	486,505	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 04 '24	Option Exercise	9.45	18,537	175,175	477,536	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 03 '24	Sale	245.14	27,845	6,825,976	458,999	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 05 '24	Sale	243.36	27,506	6,693,790	458,999	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 04 '24	Sale	242.91	18,537	4,502,823	458,999	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 05 '24	Option Exercise	9.45	27,613	260,943	213,348	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 03 '24	Option Exercise	9.45	27,407	258,996	213,142	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 04 '24	Option Exercise	9.45	18,710	176,810	204,445	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 05 '24	Sale	243.40	27,613	6,721,081	185,735	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 03 '24	Sale	245.12	27,407	6,718,002	185,735	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 04 '24	Sale	242.96	18,710	4,545,721	185,735	Apr 05 08:50 PM
Levy Richard S	Director	Apr 01 '24	Option Exercise	63.92	11,000	703,160	21,298	Apr 03 08:47 PM
Levy Richard S	Director	Apr 01 '24	Sale	257.48	11,000	2,832,335	10,298	Apr 03 08:47 PM
BATE KENNETH	Director	Apr 01 '24	Option Exercise	57.96	21,277	1,233,187	22,475	Apr 03 08:44 PM
BATE KENNETH	Director	Apr 02 '24	Option Exercise	105.08	11,212	1,178,157	12,410	Apr 03 08:44 PM
BATE KENNETH	Director	Apr 01 '24	Sale	257.26	21,277	5,473,779	1,198	Apr 03 08:44 PM
BATE KENNETH	Director	Apr 02 '24	Sale	244.49	11,212	2,741,219	1,198	Apr 03 08:44 PM
Daly James M	Director	Apr 01 '24	Option Exercise	100.79	21,577	2,174,711	22,775	Apr 03 08:41 PM
Daly James M	Director	Apr 02 '24	Option Exercise	105.08	10,912	1,146,633	12,110	Apr 03 08:41 PM
Daly James M	Director	Apr 01 '24	Sale	257.24	21,577	5,550,544	1,198	Apr 03 08:41 PM
Daly James M	Director	Apr 02 '24	Sale	244.51	10,912	2,668,087	1,198	Apr 03 08:41 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 14 '23	Option Exercise	87.92	2,000	175,840	7,667	Dec 18 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 15 '23	Option Exercise	87.92	2,000	175,840	7,667	Dec 18 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 15 '23	Sale	238.50	2,000	477,000	5,667	Dec 18 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 14 '23	Sale	232.50	2,000	465,000	5,667	Dec 18 04:30 PM
BAKER BROS. ADVISORS LP	Director	Dec 13 '23	Buy	219.39	81,159	17,805,684	1,774,294	Dec 14 06:10 PM
BAKER BROS. ADVISORS LP	Director	Dec 14 '23	Buy	228.32	20,633	4,710,893	1,793,403	Dec 14 06:10 PM
BAKER BROS. ADVISORS LP	Director	Dec 12 '23	Buy	218.31	34,578	7,548,616	1,699,129	Dec 14 06:09 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 13 '23	Option Exercise	87.92	2,500	219,800	8,167	Dec 14 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 12 '23	Option Exercise	87.92	1,300	114,296	6,967	Dec 14 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 13 '23	Sale	225.40	2,500	563,500	5,667	Dec 14 04:30 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Dec 12 '23	Sale	217.85	1,300	283,200	5,667	Dec 14 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Dec 04 '23	Option Exercise	81.16	1,800	146,090	16,801	Dec 06 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Dec 05 '23	Option Exercise	87.09	1,000	87,090	16,001	Dec 06 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Dec 04 '23	Sale	218.87	1,800	393,964	15,001	Dec 06 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Dec 05 '23	Sale	227.33	1,000	227,330	15,001	Dec 06 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Nov 29 '23	Option Exercise	73.75	4,000	295,000	19,001	Dec 01 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Nov 30 '23	Option Exercise	73.75	3,000	221,250	18,001	Dec 01 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Nov 29 '23	Sale	199.19	4,000	796,750	15,001	Dec 01 04:30 PM
Lynch Brian Joseph	SVP and General Counsel	Nov 30 '23	Sale	204.58	3,000	613,730	15,001	Dec 01 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MDGL

Madrigal Pharmaceuticals Inc

Upgrade your FINVIZ experience